Quantcast

Latest Organofluorides Stories

2014-08-18 23:02:59

The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August 18, 2014 People diagnosed with early-stage non-squamous non-small cell lung cancer whose tumors have an altered ALK gene now have the opportunity to participate in a new phase III clinical trial, ECOG-ACRIN announced today. The trial will determine if Xalkori® (generic name crizotinib, an ALK-inhibitor), when used after...

2014-08-16 23:02:22

The Firm is representing numerous clients in Risperdal lawsuits that allege gynecomastia, or male breast development, due to their use of the antipsychotic drug. New York, NY (PRWEB) August 16, 2014 A Risperdal (http://www.lawreward.com/risperdal/) meeting is scheduled to take place next month in the Philadelphia Court of Common Pleas, where hundreds of lawsuits over the antipsychotic medication are continuing to move forward, Bernstein Liebhard LLP reports. According to a Calendar...

2014-08-14 08:29:11

CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall Street Audience SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in...

2014-08-12 23:10:34

A Rise In Lipitor Lawsuit Claims Jumped In Five Months With Filings That Contend Development Of Type 2 Diabetes After Taking The Cholesterol Lowing Medication, Notes Wright & Schulte LLC Columbus, OH (PRWEB) August 12, 2014 The harmful drug attorneys at Wright & Schulte LLC have learned through a Reuters analysis that Lipitor diabetes lawsuits filed against Pfizer Inc. have spiked over the past five months primarily due to all federally filed Lipitor lawsuit claims consolidated in...

2014-08-12 23:02:26

The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin. New York, New York (PRWEB) August 12, 2014 Lipitor lawsuits (http://www.thelipitorlawsuit.com/) that claim the popular statin medication caused patients to develop Type 2 diabetes continue to mount in a federal multidistrict litigation underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports....

2014-08-12 08:30:30

SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Hirth is an industry leader and innovator with over 30 years of biotechnology and pharmaceutical discovery and development experience. A pioneer in the field of personalized medicine, Dr. Hirth led the organizations that developed both Sutent(®) and Zelboraf(®);...

2014-08-11 23:07:45

Zoloft Birth Defect Lawsuits Filed Allege SSRI Antidepressant Caused Children to Be Born with Various Congenital Malformations, Including Atrial Septal Defect; Persistent Pulmonary Hypertension of the Newborn, Neural Tube Defects, and Craniofacial Defects Reports Wright & Schulte LLC Columbus, OH (PRWEB) August 11, 2014 Wright & Schulte LLC, a nationally-recognized law firm representing plaintiffs in Zoloft lawsuits, notes that 13 new claims were recently filed in West Virginia...

2014-08-11 12:26:57

Significant Opportunity Exists for New Therapies to Treat GIST, Particularly those for Treating Unresectable and/or Metastatic Disease in Later-Line Settings BURLINGTON, Mass., Aug. 11, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through 2023 as no new therapies are expected to launch for this indication. Treatment of GIST is largely dependent on tumor size, location and growth rate and...

2014-08-11 08:28:44

PITTSBURGH, Aug. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.(1) CEO...

2014-08-11 08:28:42

LONDON, August 11, 2014 /PRNewswire/ -- Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF(R) (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.